Result of AGM and Completion of Placing

RNS Number : 4522Y

Byotrol PLC

08 September 2015

 

8 September 2015

Byotrol plc

RESULT OF AGM AND COMPLETION OF PLACING

Byotrol plc ("Byotrol" or the "Company", the developer of anti-microbial technologies, confirms that at its Annual General Meeting held earlier today, all resolutions were duly passed, without amendment.

Accordingly, as set out in the announcement dated 20 August 2015, the Company is pleased to announce the issue of the 9,261,584 Second Tranche Shares, subject to Second Admission, in conjunction with the Placing and Subscription of 43,016,796 New Ordinary Shares at 3.25 pence per share to raise approximately £1.4m before expenses.

In order to be able to issue the Second Tranche Shares, the Company will utilise its new share authorities, approved at Annual General Meeting.

Application has been made for admission of the 9,261,584 Second Tranche Shares, which is expected to occur and for dealings to commence in these New Ordinary Shares on 9 September 2014. The Second Tranche Shares will rank pari passu with the existing Ordinary Shares currently traded on AIM. 

Following Second Admission, there will be 268,051,565 Ordinary Shares in issue. The figure of 268,051,565 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Byotrol under the Disclosure and Transparency Rules.

Capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement released on 20 August 2015.

Enquiries:

Byotrol plc	01925 742 000
David Traynor - Chief Executive Dawn Marshall - Group Marketing Controller
finnCap Ltd	020 7220 0500
(Nominated Adviser & Broker)
Geoff Nash/Carl Holmes/James Thompson - Corporate Finance
Mia Gardner - Corporate Broking

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, maximising insights to identify, develop, formulate and commercialise cutting-edge antimicrobial technologies delivered in direct sales and in long-term licensing partnerships with consumer and professional multi-nationals.

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

For more information, please go to www.byotrol.co.uk

 

END

 

 

RAGLPMATMBMMBJA